Alternative Pluripotent Stem Cell Therapies Enhancement Act
Mr. Speaker, I want to make sure I am actually speaking on the right bill, and I am speaking to the Alternative Pluripotent Stem Cell Therapies Enhancement Act, and I thank my colleague from Colorado for yielding. I do rise in opposition…
Mr. Speaker, I want to make sure I am actually speaking on the right bill, and I am speaking to the Alternative Pluripotent Stem Cell Therapies Enhancement Act, and I thank my colleague from Colorado for yielding.
I do rise in opposition to a politically motivated bill brought to this House today to provide cover for certain Members who have tough elections ahead of them. It seems really simple: Vote for one type of stem cell research and then you can oppose another. This way you can appeal to voters on both sides of the issue.
But this bill is rather meaningless because there is nothing preventing researchers now from conducting research on stem cells derived from sources other than embryos.
I wish to enter into the Record a letter from the American Society for Cell Biology, which contains 27 signatories including Nobel Prize winners, chancellors of universities, researchers from across this country who are opposing this legislation not because it is evil but because it is a waste of resources.
The truth is there exists no way to extract embryonic stem cells without then having to discard those embryos, which, by the design of the underlying legislation, would have been discarded anyway. This would not be done without the expressed approval of the donating parent.
If you truly support giving hope to the millions of Americans who suffer today from diseases like ALS, cancer, Alzheimer's, diabetes, then you support feasible embryonic stem cell research that can be done today.
And those of you who claim that there is no hope for stem cell research are wrong. NIH-funded research, limited as it currently is, has already shown definite progress in this area. In the case of heart disease, scientists have been able to successfully use stem cells to create and transplant living heart cells in rats. The promise of these advancements for the human heart is incredible. This is surely a pro- life piece of legislation if there ever was one.
And there are so many more examples of the lifesaving potential of the
stem cell research we already know about, but our scientific researchers only need the resources to do this.
So I urge my colleagues to join me in voting ``no'' on this bill as a show of support for enactment into law of H.R. 810, voted for in a bipartisan way in this House, today voted for in the Senate. This is what the American people want. This is what we have supported. This is the only vehicle by which we can ensure expanded stem cell research and the ability to save lives.
The American Society
for Cell Biology,
Bethesda, MD, July 17, 2006.
Hon. Orrin Hatch,
U.S. Senate, Washington, DC.
Dear Senator Hatch: The Senate will shortly be considering
legislation to permit the National Institutes of Health (NIH)
to fund research with additional and new and existing human
embryonic stem cell (hESC) lines. As staunch supporters of
biomedical research and particularly research with hESCs, we
trust that you will exert your influence to ensure passage of
H.R. 810. Scientists engaged in ESC research are counting on
you and like-minded Senate colleagues to assure its passage.
The President must also be persuaded not to veto this
legislation, for if we continue on the path he set 5 years
ago, United States investigators will be out of the running
in converting embryonic stem cells into important new
therapies. It is especially frustrating and demeaning that
American scientists are prohibited from using their NIH grant
funds for research with the hundreds of hESC lines generated
outside the United States or generated in this country with
private funding.
Also, S. 2754, the ``Alternative Pluripotent Stem Cell
Therapies Enhancement Act,'' sponsored by Senators Specter
and Santorum, seems to us, superfluous. Ostensibly, it is
intended to authorize research ``to derive human pluripotent
stem cell lines using techniques that do not harm embryos.''
However, at present, such research is currently permissible
and, therefore, does not require congressional legislation;
indeed, the National Institutes of Health may currently be
funding such efforts.
Moreover, all the alternative procedures advanced in the
report by the President's Council on Bioethics and other
alternative methods that have been suggested encounter
equally vexing ethical concerns. Hence, S. 2754 is unneeded
and if passed would deflect from the current urgent need for
generating new stem cell lines from excess IVF-derived
blastocysts.
Sincerely,
Peter Agre, M.D., Vice Chancellor for Science and
Technology, James B. Duke Professor of Cell Biology, Duke
University School of Medicine, Nobel Prize in Chemistry,
2003; Bruce Alberts, Professor of Biochemistry and
Biophysics, University of California, San Francisco,
President Emeritus, National Academy of Sciences; Mary C.
Beckerle, Ph.D., Ralph E. and Willia T. Main, Presidential
Professor, University of Utah, President, American Society
for Cell Biology; David Baltimore, President, California
Institute of Technology, Nobel Prize in Physiology or
Medicine, 1975; Paul Berg, Cahill Professor of Biochemistry,
Emeritus, Stanford University, Nobel Prize in Chemistry,
1980; J. Michael Bishop, Nobel Prize in Physiology or
Medicine, 1989; Helen M. Blau, Ph.D., Donald E. and Delia B.
Baxter, Professor, Director, Baxter Laboratory in Genetic
Pharmacology, Stanford University School of Medicine.
Michael S. Brown, MD, Nobel Prize in Physiology or
Medicine, 1985; Linda Buck, Ph.D., Howard Hughes Medical
Institute, Division of Basic Sciences, Fred Hutchinson Cancer
Research Center, Nobel Prize in Physiology or Medicine, 2004;
Johann Deisenhofer, Regental Professor, Investigator, Howard
Hughes Medical Institute, The University of Texas
Southwestern Medical Center, Nobel Prize in Chemistry, 1988;
Joseph L. Goldstein, M.D., Regental Professor of Molecular
Genetics and Internal Medicine, University of Texas
Southwestern Medical Center at Dallas, Nobel Prize in
Physiology or Medicine, 1985; Larry Goldstein, Investigator,
Howard Hughes Medical Institute, Department of Cellular and
Molecular Medicine, University of California, San Diego
School of Medicine; Alfred G. Gilman, M.D., Ph.D., Dallas,
Texas, Nobel Prize in Physiology or Medicine, 1994; Paul
Greengard, Professor, The Rockefeller University, Nobel Prize
in Physiology or Medicine, 2000; Lee Hartwell, Ph.D.,
President & Director, Fred Hutchinson Cancer Research Center,
Nobel Prize in Physiology or Medicine, 2001; Dudley
Herschbach, Baird Research Professor of Science, Harvard
University, Nobel Prize in Chemistry, 1986.
H. Robert Horvitz, Professor of Biology, Massachusetts
Institute of Technology, Nobel Prize in Physiology or
Medicine, 2002; Douglas Koshland, Carnegie Institution,
Investigator, Howard Hughes Medical Institute; Paul C.
Lauterbur, Center for Advanced Study Professor of Chemistry &
Distinguished Professor of Medical Information Sciences,
University of Illinois, Nobel Prize for Physiology or
Medicine, 2003; Sean J. Morrison, Investigator, Howard Hughes
Medical Institute, Director, Center for Stem Cell Biology,
University of Michigan; Eric N. Olson, Department of
Molecular Biology, University of Texas, Southwestern Medical
Center at Dallas; Thomas D. Pollard, MD, Sterling Professor
and Chair, Molecular Cellular and Developmental Biology, Yale
University; Randy Schekman, HHMI Investigator, Dept. of
Molecular and Cell Biology, University of California,
Berkeley; Phillip A. Sharp, Institute Professor and Center
for Cancer Research, Massachusetts Institute of Technology,
Nobel Prize in Physiology or Medicine, 1993; Maxine F.
Singer, A.B., Ph.D., D.Sc., President Emerita, Carnegie
Institution of Washington; Harold Varmus, MD, President,
Memorial Sloan-Kettering Cancer Center, Chair, Joint Steering
Committee for Public Policy, Former Director, National
Institutes of Health, Nobel Laureate in Medicine or
Physiology, 1989; Eric Wieschaus, Department of Molecular
Biology, Princeton University, Nobel Prize in Physiology or
Medicine, 1995.